Dottor Marco Marino

Medico Chirurgo specializzato in Gastroenterologia ed Endoscopia Digestiva a Udine

Dottor Marco Marino gastroenterologo Udine

Dal settembre 2023 nominato Responsabile S.O.S. di Malattie Infiammatorie Croniche Intestinali c/o la S.O.C. di Gastroenterologia dell’ASUFC

Dal 2023 docente presso la scuola di specializzazione in Gastroenterologia presso la Facoltà di Medicina e Chirurgia dell’Università di Trieste.

Dal 2021 al 2022 componente del Nucleo Ricerca Clinica dell’Azienda Sanitaria Universitaria Friuli Centrale

Dal 2019 cultore della materia per il settore MED/12 Gastroenterologia c/o la Facoltà di Medicina e Chirurgia dell’Università di Udine 

Dal 2017 insegnamento di Gastroenterologia del corso integrato delle Malattie Gastroenteriche, endocrine, metaboliche del Corso di Laurea Magistrale a Ciclo unico in Medicina e Chirurgia ad Udine

dal 2003- Dirigente Medico c/o la S.O.C. di Gastroenterologia dell’Azienda Sanitaria Universitaria Friuli Centrale in Udine

2003 – Specializzazione in Gastroenterologia presso l’Università di Udine

1999 – registration at the General Medical Council registration (UK) 

1998 – Laurea in Medicina e Chirurgia presso l’Università di Udine

Chi sono

Sono un medico chirurgo specializzato in Gastroenterologia ed Endoscopia Digestiva e da oltre 20 anni mi occupo delle patologie gastro-intestinali dal punto di vista clinico, diagnostico e terapeutico. Nel 1999 ho ottenuto l’abilitazione medica presso il General Medical Council del Regno Unito. Dopo aver terminato la specializzazione sono diventato dirigente medico presso la Struttura Operativa complessa di Gastroenterologia presso l’Azienda ospedaliero universitaria Friuli Centrale di Udine dove vi lavoro da oltre 20 anni. Ho fatto anche una breve parentesi lavorativa presso il Leicester Royal Infirmary Hospital in Gran Bretagna. Dal 2023 sono diventato responsabile della Struttura Operativa Semplice di Malattia Infiammatorie Croniche Intestinali.

Sono stato Presidente regionale dell’AIGO (Associazione Italiana Gastroenterologi Ospedalieri) e sono socio attivo della stessa AIGO, della ECCO (European Crohn’s and Colitis Organization), della IG-IBD (Gruppo Italiano per le Malattie Infiammatorie Croniche Intestinali) e della BSG (British Society of Gastroenterology). Attualmente sono rappresentante regionale della IG-IBD e mi occupo dell’organizzazione regionale di incontri, congressi e progetti di ricerca

Ho al mio attivo numerose pubblicazioni su giornali medici internazionali indicizzati. Sono stato speaker in diversi congressi sia in Italia che all’estero. Sono docente presso la Facoltà di medicina e Chirurgia di Udine e correlatore di tesi di laurea per laureandi in Medicina e Chirurgia. Nell’ambito delle malattie infiammatorie croniche intestinali (MICI) sono investigatore principale (Principal Investigator) in studi randomizzati multicentrici internazionali su nuovi farmaci biotecnologici. Inoltre sempre in ambito delle MICI mi occupo di ricerca sia di base (immunofisiopatologia) che clinica.

Dal 2023 sono professore a contratto presso la scuola di specializzazione in Malattie dell’Apparato Digerente presso la Facoltà di Medicina e Chirurgia dell’Università di Trieste.

Il mio Curriculum

Laureato in Medicina e chirurgia a presso l’Università degli Studi di Udine nel 1998, abilitato nel 1999 e successivamente specializzato nel 2003 in Gastroenterologia ed Endoscopia digestiva. Abilitato anche in Regno Unito presso il General Medical Council dal 1999. Attualmente sono dirigente medico presso la Struttura Operativa Complessa di Gastroenterologia dell’Azienda Ospedaliero Universitaria Friuli Centrale.

Nel 2012 mi hanno conferito l’incarico professionale ad alta specializzazione in “enteroscopia diagnostico operativa nella patologia dell’intestino tenue”. Autore di diverse pubblicazioni su giornali internazionali e coordinatore di diversi studi nazionali ed internazionali sopratutto sull’utilizzo di terapie innovative nel campo della malattie infiammatorie intestinali. Ha in corso progetti di ricerca in Italia e all’estero.

Dal 2019 sono cultore della materia presso la Facoltà di Medicina e Chirurgia dell’Università di Udine dove svolgo regolarmente lezioni agli studenti del Corso di Laurea Magistrale in Medicina e Chirurgia.

Sono responsabile della Struttura Operativa Semplice di Malattie Infiammatorie Croniche Intestinali della S.O.C. di Gastroenterologia dell’Azienda Ospedaliero Universitaria Friuli Centrale (ambulatorio delle Malattie Infiammatorie Croniche Intestinali – Colite Ulcerosa e malattia di Crohn)

Sono referee delle seguenti riviste: World Journal of Gastroenterology, Frontiers Pharmacology, Inflammatory Intestinal Diseases

Eseguo qualunque tipo di endoscopia digestiva diagnostica e terapeutica inclusa l’endoscopia con videocapsula per lo studio del tratto gastrointestinale.

Esperienze

Udine – da Novembre 2003 ad oggi

Dirigente Medico in Gastroenterologia
S.O.C. di Gastroenterologia – Azienda Sanitaria Universitaria Friuli Centrale

Cultore della Materia presso la Facolta’ di Medicina e Chirurgia di Udine

Associate Specialist
Digestive Diseases Centre at the Leicester Royal Infirmary Hospital (UK)

Referenze

  • Prof. Giovanni Terrosu, Professor of Surgery. University Academic General Hospital of Udine Italy – giovanni.terrosu@uniud.it
  • Debora Berretti MD, Senior Consultant at Gastroenterology University General Hospital of Udine Italy. – berretti.deboraaoud.sanita.fvg.it
  • Prof. Janusz Jankowski – Consultant in Medicine, University Hospitals of Leicester NHS Trust, Honorary Consultant in Gastroenterology, Oxford Radcliffe Hospitals Trust  – janusz.jankowskiclinpharm.ox.ac.uk
  • Peter Wurm Consultant in Gastroenterology University Hospital of Leicester (UK) – peter.wurmuhltr.nhs.uk

GRANTS

  • Cooperative Interregional Study IIIa Italia-Slovenia about Coeliac disease European Community funds.
  • In 2019 Grant from Takeda International for the project: Potential role of exosomes in determining the different clinical response to Vedolizumab in TNFα naïve vs TNFα-exposed UC/CD patients Tracking Number: IISR-2019-102877

STUDI CLINICI DI FASE 2, 3 e 4 TERMINATI ED IN CORSO

  • Post-Marketing Observational Cohort Study of Patients with Inffiammatory Bowel Disease (IBD) Treated with CT-P13 in Usual Clinical Practice (CONNECT-IBD)
  • Subinvestigator of REMICADECRD3001: prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (inffiximab) and Placebo in the Prevention of Recurrence in Crohns Disease Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
  • Principal Investigator of CNTO1275CRD3002: A Phase 3, Randomized, Double-blind, Placebocontrolled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohns Disease (UNITI-2)
  • Principal Investigator of CNTO1275CRD3001: A Phase 3, Randomized, Double-blind, Placeb0- controlled, Parallelgroup, lVIulticenter Study to Evaluate the Safety and Efficacy of Ustekinumab lnduction Therapy in Subjects with lVIoderately to Severely Active Crohn’s Disease Vho Bave Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1).
  • Principal Investigator of CNTO1275CRD3003: A Phase 3, Randomized, Double-blind, Placebocontrolled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Severely Active Crohns Disease (IMUNITI)
  • Principal Investigator of: A Randomised Dose Optimisation Study to Evaluate the Efficacy and Safety of Cobitolimod in Moderate to Severe Active Ulcerative Colitis Patients (Phase II b)
  • Principal Investigator of: phase III, randomized, multicenter double-blind, double-dummy study to evaluate the efficacy and safety of etrolizumab compared with inffiximab in patients with moderate to severe active ulcerative colitis who are naive to tnf inhibitor.
  • Principal Investigator of TRIDENT: a Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohns Disease (Protocol 64304500CRD2001; Phase 2b JNJ-64304500)
  • Principal Investigator of STARDUST: Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohns Disease Patients Treated with Ustekinumab. PROTOCOL NUMBER: CNTO1275CRD3005
  • Principal Investigator of TIGENIX: a phase III, randomized, double blind, parallel group, placebo controlled, international, multicentre study to assess efficacy and safety of Cx601, adult allogeneic expanded adipose-derived stem cells (eASC), for the treatment of complex perianal fistula(s) in patients with Crohns disease over a period of 24 weeks and a follow-up period up to 52 weeks. ADMIRE-CD II study
  • Principal Investigator of VIBRATO: a phase 2b, double-blind, randomized, placebo-controlled, parallel group, dose ranging study of oral pf-06651600 and pf-06700841 as induction and chronic therapy in subjects with moderate to severe ulcerative colitis
  • Principal Investigator of LUCENT 1: Protocol I6T-MC AMAN. A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic Failed Patients with Moderately to Severely Active ulcerative Colitis
  • Principal Investigator of LUCENT 2: Protocol I6T MC-AMBG A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis
  • Principal Investigator of Yellowstone: induction study #1 – a phase 3, multicenter, randomized, double-blind, placebo-controlled study of oral ozanimod as induction therapy for moderately to severely active crohns disease
  • Principal Investigator of of Yellowstone: a phase 3, multicenter, randomized, double-blind, placebo-controlled study of oral ozanimod as maintenance therapy for moderately to severely active crohns disease
  • Principal Investigator of Yellowstone: a phase 3, open label extension of study of oral ozanimod for moderately to severely active Crohns disease
  • Principal Investigator of GALAXI: A Phase 2/3, Randomized, Double-blind, Placebo- and Activecontrolled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn’s Disease
  • Principal Investigator of: a phase II, randomized, parallel-group, double-blind, double-dummy, placebo controlled, multicenter study to evaluate the efficcacy, safety, and pharmacokinetics of UTTR1147 a compared with placebo and compared with vedolizumab in patients with moderate to severe ulcerative colitis

CONGRESSI

  1. Acute and Chronic Pancreatitis: actual therapy 6/6/1998 – General Hospital of Udine (Italy)
  2. Acute Pancreatitis Villa Manin Passariano (UD) dal 9 al 10 giugno 2000.
  3. 8th UNITED EUROPEAN GASTROENTEROLOGY WEEK Brussels 2000 (Belgium)
  4. Corso Residenziale per gli specializzandi di gastroenterologia tenutosi a Chianciano Terme dal 28 al 29 settembre 2000.
  5. Atelier; food and wellness 29-30 of September 2000 – Chianciano Terme (Italy).
  6. Has liver transplant modiffied the management of the cirrhotic patient? Prof. A. K. Burroughs – General Hospital of Udine (Italy) on 14 November 2000.
  7. EVIDENCE-BASED Gastroenterology; III course Torgiano (Italy) from 10 to 12 December 2000
  8. GEEMO Meeting 2001 & Postgraduate Corse On Esophageal Disease Abano Terme (Italy) 29-31 of March 2001
  9. 36th Annual Meeting of EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 18-22 of april 2001 (Prague – CZ)
  10. Percutaneous Endoscopic gastrostomy: indications and techniques. Monfalcone (Italy), 11 of may, 2001.
  11. Update on esophageal motilità Gastroenterology and Endoscopic Unit of Istituto S. Raffaele of Milan (ITALY) from 31 to 2 of July 2001
  12. GERD: a further progress to understand the disease Rome, 29 of September 2001.
  13. First joined workshop on therapeutic endoscopy (Torino-Toronto). Torino (Italy) 13-15 September 2001
  14. Familial adenomatous polyposis Gastroenterology Unit Hospital of Aviano (Italy) on 12 October 2001.
  15. 2 Internal Medicine Congresso of Friuli Venezia Giulia General Hospital of Gemona (Italy) 13 October 2001.
  16. Prevention and Therapy of chronic viral hepatitis. Verona (Italy), 9 of February 2002.
  17. Colon Cancer: mini invasive surgery? Udine (Italy), 25 May 2002
  18. Chronic Hepatitis C: diagnostic and therapeutic update. Udine (Italy), 14 September 2002
  19. GERD e miniinvasive treatment (laparoscopic and robotic management). Magnano in Riviera (Italy), 28 September 2002.
  20. Digestive Disease Week. New Orleans (USA), May 15-20, 2004
  21. XVI Symposium. IBD: from pathogenesis to clinical practice. Padua (ITALY), January 28-29, 2005
  22. EUS and ERCP: an integrated future? A 2005 Consensus. Reggio Emilia on February 18-19, 2005
  23. United European Gastroenterology 2005 Denmark
  24. United European Gastroenterology 2006 Berlin
  25. Digestive Disease Week 2009 Chicago
  26. European Crohn’s and Colitis Organization 2009 – Wien
  27. United European Gastroenterology 2009 London
  28. United European Gastroenterology 2010 New Orleans
  29. European Crohn’s and Colitis Organization Dublin 2011
  30. Digestive Disease Week 2011 Chicago
  31. Digestive Disease Week 2012
  32. United European Gastroenterology 2013
  33. United European Gastroenterology 2014
  34. European Crohn’s and Colitis Organization 2015 BARCELONA, SPAIN
  35. United European Gastroenterology 2015 Barcelona, Spain
  36. United European Gastroenterology2016 Wien, Austria
  37. European Crohn’s and Colitis Organization 2018, Wien, Austria
  38. European Crohn’s and Colitis Organization 2019 Copenaghen. Denmark
  39. European Crohn’s and Colitis Organization 2020 Wien. Austria
  1. Parisi G, Bottona E, Carrara M, Cardin F, Faedo A, Goldin D, Marino M, Pantalena M, Tafner G, Verdianelli G, Zilli M, Leandro G. Treatment effects of partially hydrolyzed guar gum on symptoms and quality of life of patients with irritable bowel syndrome. A multicenter randomized open trial. Dig Dis Sci. 2005 Jun;50(6):1107-12.
  2. Maieron R, Elli L, Marino M, Floriani I, Minerva F, Avellini C, Falconieri G, Pizzolitto S, Zilli M. Celiac disease and intestinal metaplasia of the esophagus (Barrett’s esophagus). Dig Dis Sci. 2005 Jan;50(1):126-9.
  3. Stefano Passalacqua, Pietro Manuel Ferraro, Giampaolo Bresci, Valeria D’Ovidio, Marco Astegiano, Mariabeatrice Principi, Roberto Testa, Renata D’Incà, Daniela Valpiani, Alessandro Armuzzi, Renato Sablich, Flaminia Cavallaro, Francesco Costa, Vincenza Di Leo, Elisabetta Colombo, Alessia Santini, Annalisa Aratari, Pierenrico Lecis, Valeria Saladino, Gabriele Riegler, Marino Marco, Francesca Calella, Chiara Ricci, Maria Luisa Guidi, Giuseppe Repaci, Michele Silla. The Italian Registry of Therapeutic Apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study. J Clin Apher. 2011 Dec;26(6):332-7.
  4. Faleschini G1, Vadalà di Prampero SF, Bulajic M, Baccarani U, Toniutto P, Panic N, Zoratti LM, Marino M, Zilli M. Predictors of endoscopic treatment outcome in the management of biliary complications after orthotopic liver transplantation. Eur J Gastroenterol Hepatol. 2015 Feb;27(2):150-4.
  5. Sorrentino D, Marino M, Dassopoulos T, Zarifi D, Del Bianco T. Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab. PLoS One. 2015 Dec 15;10(12):e0144900. doi: 10.1371/journal.pone.0144900. eCollection 2015
  6. Frossi B, Tripodo C, Guarnotta C, Carroccio A, De Carli M, De Carli S, Marino M, Calabrò A, Pucillo CE.. Mast cells are associated with the onset and progression of celiac diseaseJ J Allergy Clin Immunol. 2016 Sep 13. pii: S0091-6749(16)30948-4
  7. Brian G. Feagan, M.D., William J. Sandborn, M.D., Christopher Gasink, M.D., Douglas Jacobstein, M.D., Yinghua Lang, M.A., Joshua R. Friedman, M.D., Ph.D., Marion A. Blank, Ph.D., Jewel Johanns, Ph.D., Long-Long Gao, Ph.D., Ye Miao, M.S., Omoniyi J. Adedokun, M.S., R.Ph., Bruce E. Sands, M.D., Stephen B. Hanauer, M.D., Severine Vermeire, M.D., Ph.D., Stephan Targan, M.D., Subrata Ghosh, M.D., Willem J. de Villiers, M.D., Ph.D., Jean-Frédéric Colombel, M.D., Zsolt Tulassay, M.D., Ursula Seidler, M.D., Bruce A. Salzberg, M.D., Pierre Desreumaux, M.D., Scott D. Lee, M.D., Edward V. Loftus, Jr., M.D., Levinus A. Dieleman, M.D., Ph.D., Seymour Katz, M.D., and Paul Rutgeerts, M.D., Ph.D., for the UNITI–IM-UNITI Study Group. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med 2016; 375:1946-1960. November 17, 2016. UNITI-1 Investigators (UNITI-1 Study Group) IM-UNITI Investigators (IM-UNITI Study Group): Dr Marco Marino
  8. Vadala di Prampero S,Marino M, Toso F, Avellini C, Nguyen V, Sorrentino Isolated Bilateral Gastrocnemius Myositis in Crohn Disease Successfully Treated with Adalimumab. Case Rep Gastroenterol. 2016 Nov 7;10(3):661-667
  9. G Terrosu, V Cherchi, S Calandra, A Esposito, M Marino, D Berretti, A Risaliti. A Particular Use of Endobag ®: Extraction of Rectal Foreign Bodies. Case Rep Med 2017;2017:8909706. doi: 10.1155/2017/8909706
  10. Panic N, Macchini F, Solito S, Boccia S, Leoncini E, Larghi A, Berretti D, Pevere S, Vadala S, Marino M, Zilli M, Bulajic M. Prevalence of Extrapancreatic Malignancies Among Patients With Intraductal Papillary Mucinous Neoplasms of the Pancreas. 2018 May 17. Doi 10.1097/MPA.0000000000001072
  11. Vadalà di Prampero, Solito S, Faleschini G, Panic N, Castriotta L, Picci A, Pinese E, Piva R, Bulajic M, Marino M, Rossitti P, Zilli M. The Impact of Dietician Support and Behavioural Therapy in Addition to Concomitant Treatment with Intragastric Balloon in Obese Patients. Obes Surg. 2020 Feb;30(2):612-617
  12. Rossana Domenis, Marco Marino, Adriana Cifù, Giulia Scardino, Francesco Curcio, Martina Fabris. Circulating exosomes express α4β7 integrin and compete with CD4+ T cells for the binding to Vedolizumab. PLoS One. 2020; 15(11): e0242342. Published online 2020 Nov 12. doi: 10.1371/journal.pone.0242342
  13. Emanuele Rondonotti, Cristiano Spada, Sergio Cadoni, Renato Cannizzaro, Carlo Calabrese, Roberto de Franchis, Luca Elli, Carlo Maria Girelli, Cesare Hassan, Riccardo Marmo, Maria Elena Riccioni, Salvatore Oliva, Giuseppe Scarpulla, Marco Soncini, Maurizio Vecchi, Marco Pennazio, “RAVE Study “RAVE Study Group”: Stefano Ambrogio Bargiggia, Alessandra Bizzotto, Valentina Boarino, Fabrizio Bossa, Rosamaria Bozzi, Mauro Bruno, Andrea Buda, Marisa Buono, Danilo Castellani, Flaminia Cavallaro, Linda Ceccarelli, Laura Centenara, Paola Ciamarra, Giovanni Comi, Debora Compare, Giovanna Condino, Claudio Camillo Cortelezzi, Marco Daperno, Elena Di Girolamo, Kostantinos Efthymakis, Maurizio Ferrante, Fabiola Fornaroli, Giusi Franco, Tommaso Gabbani, Ermenegildo Galliani, Carlotta Francesca Maria Gebbia, Tiziana Grasso, Elena Iiritano, Paulin Francis Lawson, Fausto Lella, Eugenio Limido, Marta Maino, Giovanna Mandelli, Nicola Mantovani, Marco Marino, Roberta Marino, Mauro Mastronardi, Dario Moneghini, Elisabetta Morandi, Alessandro Mussetto, Chiara Notaristefano, Maurizio Pantalena, Carmelina Petruzziello, Lorena Pietrini, Lodovica Pozzi, Mariabeatrice Prinicipi, Rossella Pumpo, Maria Luisa Rega, Stefano Rodinò, Renzo Schalling, Clementina Signorelli, Maria Giuseppina Tatarella, Gian Eugenio Tontini, Filippo Torroni, Pasquale Vitagliano, Giovanna Vitale. Quality performance measures for small capsule endoscopy: Are the ESGE quality standards met? Endosc Int Open. 2021 Feb;9(2):E122-E129. doi: 10.1055/a-1319-0742.  Epub 2021 Jan 25
  14. Jaqueline Velkoski, Franco Grimaldi, Laura DI Meo, Francesca Mion, Riccardo Pravisani, Marco Marino, Sergio Calandra, Vittorio Cherchi, Giovanni Terrosu. Immunonutrition in elective colorectal surgery and early inflammatory response. Minerva Surg. 2021 Apr 23. doi: 10.23736/S2724-5691.21.08619-3
  15. Lorenzo Cereser, Giovanni Zancan, van Giovannini, Carmelo Cicciò, Ilaria Tinazzi, Angela Variola, Matteo Bramuzzo, Flora Maria Murru, Marco Marino, Annarita Tullio, Salvatore De Vita, Rossano Girometti, Alen Zabotti. Asymptomatic sacroiliitis detected by magnetic resonance enterography in patients with Crohn’s disease: prevalence, association with clinical data, and reliability among radiologists in a multicenter study of adult and pediatric population. Clin Rheumatol. 2022 Apr 7. doi: 10.1007/s10067-022-06143
  16. Calini G, Ortolan N, Battistella C, Marino M, Bresadola V, Terrosu G. Endoscopic failure for foreign body ingestion and food bolus impaction in the upper gastrointestinal tract: an updated analysis in a European tertiary care hospital. Eur J Gastroenterol Hepatol. 2023 Sep 1;35(9):962-967.
  17. Sonia Solito, Salvatore Francesco Vadalá di Prampero, Milutin Bulajic, Serena Battista, Giulia Tomassini, Nikola Panic, Katarina Jankovic, Marco Marino. Cytomegalovirus-Related Gastritis in an Immunocompetent Host Presenting With Infectious Gastroparesis. ACG Case Rep J. 2023 Dec 15;10(12):e01231

  18. Nikola Panic, Marco Marino, Goran Hauser, Silvia Jacobsen, Francesco Curcio, Francesco Meroi, Adriana Cifù, Eleonora Castagnaviz, Cinzia Pistis, Giovanni Terrosu, Milutin Bulajic, Salvatore Francesco Vadalà di Prampero, Dino Tarabar, Irena Krznaric-Zrnic, Gordana Kovacevic,Ivan Rankovic and Martina Fabris A Multiparametric Method Improves the Serological Characterization of Inflammatory Bowel Diseases: Preliminary Results from a Multicenter Eastern Europe Study. Gastrointest. Disord. 2024, 6, 152–163. https://doi.org/10.3390/gidisord6010011
  1. M Marino, Brosolo P, Minerva F, G De Pretis. Granular Cells Tumor Of The Esophagus (Abrikossoffs Tumor) Endoscopic, Echo-Endoscopic And Clinical Aspects. GEEMO Meeting 2001 & Postgraduate Corse On Esophageal Disease.
  2. Dado G, Bresaola V, Terrosu G, Marino M, Scanavacca F, Benzoni E, Zilli M, Bresaola F. Laparoscopic treatment in unknown cholelithiasis. 7 National Congress of Italian Society of laparoscopic Surgery, 2001.
  3. Brosolo P, Marino M, Minerva F, Maieron R, Avellini A, De Pretis G. Endosonographic diagnosis of Gastric Linitis Plastica. 9th United European Gastroenterology week. Endoscopy; Vol 33 (Suppl I); Novembre 2001; abstract n 1939
  4. Maieron R, Marino M, Minerva F, Brosolo P, Pizzolitto P, Avellini A, Beltrami B, De pretis G. Short- Segment Barretts Esophagus (SSBE): clinical, endoscopical and histological data. Endoscopy; Vol 33 (Suppl I); Novembre 2001; abstract n 2081
  5. Maieron R, Marino M, Minerva F, Brosolo P, Macor C, Zoratti L, Andreoli S, Zilli M. Short-Segment Barretts Esophagus (SSBE): clinical, endoscopical and histological data. 7th National Congress of Digestive Diseases, Bari (Italy), 2001. Digestive and Liver disease; Vol 33 supplement number 1 November 2001 abstract 92
  6. Elli L, Maieron R, Marino M, Panos J, Andreoli S, Macor C, Zoratti L, Berretti D, Zilli M. Celiac disease and intestinal metaplasia of the oesophagus. 8th National Congress of Digestive Diseases. 22-26 june 2002, Rome, Italy. Abstracts of Scientific Presentations. Digestive and Liver Disease 2002, vol. 34, suppl.1, A28.
  7. Carrella M, Elli L, Panos J, Zancanaro F, Marino M. Lipid synthesis in the NRC-1 and SkCha-1 cholangiocytes. DDW 2002. Gastroenterology 2002; (suppl) 123; 1 :64.
  8. Elli L, Maieron R, Marino M, Panos J, Andreoli S, Macor C, Zoratti L, Berretti D, Zilli M. Celiac disease and intestinal metaplasia of the oesophagus. 10th UEGW (Geneva). Gut 2002
  9. D. Berretti, M. Marino et al. Percutaneous Endoscopic Gastrostomy: a review of indications, complications and outcome. Digestive and Liver Disease, volume 37, supplement 1, March 2005, S173
  10. Macor, D. Berretti, M. Marino, R. Maieron, S. Pevere, P. Rossitti, L. Zoratti and M. Zilli. Successful management of bleeding duodenal varices by endoscopic injection of N-butyl-2-cyanoacrylate (glubran 2). Digestive and Liver Disease, Volume 38, Supplement 1, April 2006, Pages S52-S53 C.
  11. D. Berretti, M. Marino, C. Macor, R. Maieron, S. Pevere, P. Rossitti, L. Zoratti and M. Zilli Successful endoscopic clipping of rectal dieulafoy’s lesion:Case report. Digestive and Liver Disease, Volume 38, Supplement 1, April 2006, Page S211.
  12. M. Marino, D. Berretti, C. Macor, R. Maieron, S. Pevere, P. Rossitti, L. Zoratti and M. Zilli. Perforation of the esophagus after pneumatic dilatation treatment of esophageal stricture in a patient with eosinophilic esophagitis. Digestive and Liver Disease 2008. 40(1), 2008, Page S79
  13. D. Berretti, M. Marino, C. Macor, R. Maieron, S. Pevere, P. Rossitti, L. Zoratti, M. Zilli. Prospective evaluation of argon plasma coagulator in therapeutic gastrointestinal endoscopy. Digestive and Liver Disease, Volume 40, Supplement 1, March 2008, Pages S192-S193
  14. D. Berretti, M. Marino, C. Macor, R. Maieron, S. Pevere, P. Rossitti, L. Zoratti, M. Zilli. Argon plasma coagulator as first-line treatment for chronic radiation proctitis. Digestive and Liver Disease, Volume 40, Supplement 1, March 2008, Page S159
  15. V. Ciardo, M. Zilli, D. Berretti, C. Macor, R. Maieron, M. Marino, S. Pevere, P. Rossitti, L. Zoratti Intragastric balloon for morbid obesity: a retrospective evaluation of efficacy and tolerance Digestive and Liver Disease, Volume 40, Supplement 1, March 2008, Page S167
  16. Marino M. et Al. Endosonographic diagnosis of gastrointestinal stromal tumors associated with Carney Triad. Case report oral presentation at UEGW 2009 London.
  17. M. Marino, F. Grimaldi, D. Berretti, E. Tonutti, D Visentini, A. Trianni, M. Zilli. Is ghrelin a potential tumor marker in neuroendocrine tumors? European Journal of Clinical Investigation 2010; 40 (suppl 1): 1-23
  18. A. Balzano, F. Manguso, V. Annese, A. Benedetti, A. D’arienzo, M. Marino, M. Alberici, G. Van Assche, R. Sablich. Oral treatment of mild to moderate ulcerative colitis with beclomethasone dipropionate or prednisone. a double-blind randomized controlled trial. Digestive and Liver disease, volume 42, supplement 2, march 2010, page s181
  19. Marino M. Berretti D., Toso F., Maieron R., Zilli M.Usefulness of ultrasound in small bowel crohns disease: comparison with magnetic resonance for extension, complications and disease activity. UEGW Barcelona2010 October 23 – 27, 2010 Barcelona/Spain. Pubblished in Gut Suppplement 2010
  20. Marino M, Zucchi E., Checchin D, Lodolo I, Berretti D., Maieron R. Zilli. M. Incidental Diagnosis Of Inflammatory Bowel Disease During Bowel Cancer Screening Programme In Northeast Italy. 6th Congress of ECCO – Inflammatory Bowel Diseases 2011 February 24-26, 2011 in Dublin/Ireland. Pubblished in Journal of Crohns and Colitis 2011
  21. M Marino, D Berretti, R Maieron, P Rossitti, M Zilli Endoscopy II: Colonoscopic adverse events during bowel cancer screening programme in north-east italy: a preliminary report. Gut 2011;60:A195 22.
  22. E Berretti D, Pevere S, Marino M., Zucchi E., Lodolo I., Zilli M. Accuracy of endoscopic ultrasonography for re-staging rectal cancer after neoadjuvant chemoradiation therapy. Presented at FISMAD 2011, Torino. Digestive and Liver Disease
  23. E. Zucchi, I. Lodolo, M. Marino, G. Terrosu, D. Berretti, D. Checchin, R. Maieron, P. Rossitti, S. Vadalà e M. Zilli. Initial experience of colon rectal cancer screening programme in a single center in Friuli Venezia Giulia (Italy) . Presented at FISMAD 2011, Torino Digestive and Liver Disease
  24. M Marino, D Berretti, F Toso, Z Maurizio. Inflammation bowel disease II: Usefulness of ultrasound in small bowel crohn’s disease: comparison with magnetic resonance for extension, complications and disease activity. Gut 2011;60:A210
  25. Marino M, Zucchi E., Terrosu G., Berretti D., Lodolo I., Maieron R., Zilli m. et al. Relationship among colorectal cancer, advanced histology and polyp size in patients undergoing screening colonoscopy in north eastern Italy. DDW 2011 Chicago/USA. Pubblished on Gastroenterology 2011 vol 140, 5:s-415
  26. Marco Marino, Elena Zucchi, Milutin M. Bulajic, Debora Berretti, Piera Rossitti, Maurizio Zilli. The Burden of CRC Screening: Number and Cost Estimation of Follow-up Colonscopies During CRC Screening Program in a North-Eastern Italian Single Tertiary Center. Gastroenterology 2012 Vol. 142, Issue 5, Supplement 1, Page S-777
  27. Milutin M. Bulajic, Brigita D. Smolovic, Nikola Panic, Miodrag Radunovic, Maurizio Zilli, Marco Marino, Aleksandra R. Pavlovic Markovic, Zoran Krivokapic, Mirko Bulajic, Thomas Rösch. High-Risk Group Targeting Colorectal Cancer Screening May Be More Adequate for Countries With Lower Incidence Compared With Average-Risk Population Screening: The Montenegro Experience. Gastroenterology Vol. 144 2012, Issue 5, Supplement 1, Page S-602
  28. Marino, Marco; Dario Sorrentino, Scott Hauenstein, Marco Marino, Steven Lockton, Dimitra Zarifi, Tiziana Del Bianco, Sharat Singh. Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-up and Impact of Infliximab Trough Levels and Antibodies to Infliximab. Gastroenterology 2013, Volume 144, Issue 5, Supplement 1, Page S-777
  29. M Marino, E Zucchi, M Fabbro, I Lodolo, R Maieron, S Vadalà, M Zilli. Outcome of infliximab discontinuation in IBD patients and therapy rechallenging in relapsers: Single centre preliminary data S232-S233 First published online: 1 February 2014
  30. Marino Marco, Terrosu, Giovanni; Macchini, Federico; Vadala’ di Prampero, Salvatore Francesco; Bulajic, Milutin M.; Zilli, Maurizio. Body Mass Index As New Risk Factor for Postoperative Endoscopic Recurrence in Crohn’s Disease? Gastroenterology 2016, Vol. 150, Issue 4, S993
  31. R. Domenis, A. Cifu’, M. Fabris, G. Scardino, M. Zilli, M. Marino, F. Curcio. o circulating exosomes interfere with vedolizumab efficacy in IBD patients? P05 abstracts of the 14th Congress of ECCO, 2019
  32. M. Fabris, F. Meroi, A. Cifu’, E. Castagnaviz, F. Curcio, G. Terrosu, G. Scardino, S. F. Vadalà di Prampero, M. Marino. Preliminary Evaluation of a new immunoflorescence mosaic assay for inflammatory bowel disease diagnosis: a pilotstudy in Udine. P228 abstracts of the 14th Congress of ECCO, 2019
  33. Domenis R., Cifù A., Fabris M., Scardino G., Zilli M., Marino M., Curcio F. Potential Role of Exosomes in Countering Vedolizumab-Based Therapy in IBD Patients In: The FASEB Journal (2019) vol. 33 no. 1 Supplement (496.32) ISSN: 0892-6638, Experimental biology 2019 (Orlando, Florida, April 6-9)

Contatta il Dott. Marco Marino

14 + 4 =